½ÃÀ庸°í¼­
»óǰÄÚµå
1573948

¼¼°èÀÇ ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå : ¿ëµµ, ¼¼Æ÷ À¯Çü, ÃÖÁ¾ »ç¿ëÀÚ, Á¦Ç° Á¦°ø Á¦Ç°, ±â¼úº° ¿¹Ãø(2025-2030³â)

Competent Cells Market by Application (Biotechnology, Clinical Research, Industrial), Cell Type (E. coli Competent Cells, Mammalian Competent Cells, Other Bacterial Competent Cells), End User, Product Offerings, Technology - Global Forecast 2025-2030

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: 360iResearch | ÆäÀÌÁö Á¤º¸: ¿µ¹® 184 Pages | ¹è¼Û¾È³» : 1-2ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡á º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼ÛÀÏÁ¤Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀåÀº 2023³â¿¡ 20¾ï 1,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í, 2024³â¿¡´Â 22¾ï 1,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 8.76%·Î ¼ºÀåÇÏ¿©, 2030³â¿¡´Â 36¾ï 2,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

ÄÄÇÇÅÏÆ® ¼¿´Â ºÐÀÚ »ý¹°Çп¡¼­ ÇüÁúÀüȯ °úÁ¤¿¡¼­ ¿Ü·¡ DNAÀÇ Èí¼ö¿¡ ÇʼöÀûÀ̸ç, »ý¸í°øÇÐ ¿¬±¸, À¯Àü°øÇÐ ¹× ÀǾàǰ °³¹ß¿¡ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÀÌ ¼¼Æ÷µéÀº DNA¿¡ ´ëÇÑ ¸· Åõ°ú¼ºÀ» Çâ»ó½Ã۱â À§ÇØ È­ÇÐÀûÀ¸·Î ¶Ç´Â Àü±âÀûÀ¸·Î 󸮵˴ϴÙ. ÄÄÇÇÅÏÆ® ¼¿ÀÇ Çʿ伺Àº º¹Á¦ ±â¼ú, ´Ü¹éÁú ¹ßÇö, À¯ÀüÀÚ º¯Çü¿¡ ´ëÇÑ ÀÀ¿ë ¹× À¯Àü °øÇÐ ¹× ÇÕ¼º »ý¹°Çп¡ ÁßÁ¡À» µÐ ¿¬±¸¼ÒÀÇ ±âº» µµ±¸ÀÔ´Ï´Ù. ÃÖÁ¾ ¿ëµµÀÇ ¹üÀ§´Â Çмú ¿¬±¸ ±â°ü, Á¦¾à ȸ»ç, »ý¸í °øÇÐ ±â¾÷À» ´Ù·ç°í ÀÖÀ¸¸ç, ÀÌ·¯ÇÑ ¼¼Æ÷´Â À¯ÀüÀÚ º¹Á¦ ¹× ÀǾàǰ Á¦Á¶¿Í °°Àº Áß¿äÇÑ ¾÷¹«¿¡ ÇʼöÀûÀÔ´Ï´Ù.

ÁÖ¿ä ½ÃÀå Åë°è
±âÁسâ (2023³â) 20¾ï 1,000¸¸ ´Þ·¯
ÃßÁ¤³â (2024³â) 22¾ï 1,000¸¸ ´Þ·¯
¿¹Ãø³â(2030³â) 36¾ï 2,000¸¸ ´Þ·¯
º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR)(%) 8.76%

½ÃÀå ÀλçÀÌÆ®¿¡ µû¸£¸é, ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀåÀÇ ¼ºÀåÀº ÇÕ¼º »ý¹°ÇÐÀÇ Áøº¸, ÀçÁ¶ÇÕ ±â¼ú¿¡ ´ëÇÑ ÀÚ±Ý Á¦°ø Áõ°¡, ¹ÙÀÌ¿À ÀǾàǰ ¼ö¿ä Áõ°¡°¡ °ßÀÎÇϰí ÀÖ½À´Ï´Ù. À¯Àü °øÇÐÀÇ Áö¼ÓÀûÀÎ Çõ½ÅÀº ÄÄÇÇÅÏÆ® ¼¿ ¼ö¿ä¸¦ Áõ°¡½ÃŰ°í ½ÃÀå È®´ë¸¦ µÞ¹ÞħÇϰí ÀÖ½À´Ï´Ù. CRISPR ±â¼ú°ú Â÷¼¼´ë Ä¡·á °³¹ßÀÇ Áøº¸·Î ºñÁî´Ï½º ±âȸ°¡ ź»ýÇϰí ÀÌÇØ °ü°èÀÚ¿¡°Ô ÀáÀçÀûÀÎ ÆÄÆ®³Ê½Ê°ú ÅõÀÚÀÇ ±æÀÌ »ý±é´Ï´Ù. »õ·Î¿î ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϱâ À§Çؼ­´Â ƯÈ÷ »ý¸í°øÇÐ ºÎ¹®ÀÇ ±Þ¼ºÀå°ú Á¤ºÎÀÇ Àû±ØÀûÀÎ ³ë·ÂÀ» ÅëÇØ ¾Æ½Ã¾ÆÅÂÆò¾ç¿¡¼­ ½ÃÀå È®´ë¸¦ Áß½ÃÇÏ´Â °ÍÀÌ ÁÁ½À´Ï´Ù.

¹Ý´ë·Î »ý»ê°ú °ü·ÃµÈ ³ôÀº ºñ¿ë°ú À¯ÀüÀÚ Á¶ÀÛ¿¡ °üÇÑ À±¸®Àû ¿ì·Á µî ½ÃÀå ÁøÃâÀ» ÀúÇØÇÒ ¼ö ÀÖ´Â Á¦¾àµµ ÀÖ½À´Ï´Ù. ±ÔÁ¦»óÀÇ Àå¾Ö¹°°ú ¾ö°ÝÇÑ ½ÂÀÎ °úÁ¤Àº ´õ¿í ¾î·Á¿öÁö°í ÀÖ½À´Ï´Ù. ±â¼ú Çõ½Å°ú ¿¬±¸´Â DNAÀÇ Èí¼ö È¿À² Çâ»ó, ºñ¿ë È¿À²ÀûÀÎ °í´É·ü ±ÕÁÖÀÇ °³¹ß, ¼¼Æ÷ »ýÁ¸À²À» À¯ÁöÇϱâ À§ÇÑ µ¿°áº¸Á¸ ±â¼úÀÇ °³¼±¿¡ ÁßÁ¡À» µÑ ¼ö ÀÖ½À´Ï´Ù. »ý»ê °øÁ¤¸¦ °£¼ÒÈ­Çϰí ÀÚµ¿È­ Ç÷§Æû¿¡ ÅõÀÚÇÔÀ¸·Î½á Á¦Á¶ ¹× È®À强À» ÃÖÀûÈ­ÇÒ ¼ö ÀÖ½À´Ï´Ù. ½ÃÀåÀÇ ¼ºÁúÀº ¸Å¿ì ¿ªµ¿ÀûÀÌ¸ç ±Þ¼ÓÇÑ ±â¼ú Áøº¸¿Í ±âÁ¸ ½ÅÈï Âü°¡ ±â¾÷ÀÌ ½ÃÀå Á¡À¯À²À» ´ÙÅõ´Â °æÀï ±¸µµ¸¦ Ư¡À¸·ÎÇÕ´Ï´Ù. ±â¼ú Çõ½ÅÀ» ¾÷°è ¼ö¿ä¿¡ ¸ÂÃß°í ±ÔÁ¦ ¹®Á¦¸¦ ÇØ°áÇÔÀ¸·Î½á ±â¾÷Àº Áö¼ÓÀûÀÎ ¼ºÀå°ú °æÀï ¿ìÀ§¸¦ ´Þ¼ºÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ : ºü¸£°Ô ÁøÈ­ÇÏ´Â ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀåÀÇ ÁÖ¿ä ½ÃÀå ÀλçÀÌÆ® °ø°³

ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀåÀº ¼ö¿ä ¹× °ø±ÞÀÇ ¿ªµ¿Àû ÀÎ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ º¯¸ðÇϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ½ÃÀå ¿ªÇÐÀÇ ÁøÈ­¸¦ ÀÌÇØÇÔÀ¸·Î½á ±â¾÷Àº ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÅõÀÚ°áÁ¤, Àü·«Àû °áÁ¤ Á¤¹ÐÈ­, »õ·Î¿î ºñÁî´Ï½º ±âȸ ȹµæ¿¡ ´ëºñÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ µ¿ÇâÀ» Á¾ÇÕÀûÀ¸·Î ÆÄ¾ÇÇÔÀ¸·Î½á ±â¾÷Àº Á¤Ä¡Àû, Áö¸®Àû, ±â¼úÀû, »çȸÀû, °æÁ¦Àû ¿µ¿ª¿¡ °ÉÄ£ ´Ù¾çÇÑ ¸®½ºÅ©¸¦ °æ°¨ÇÒ ¼ö ÀÖÀ» »Ó¸¸ ¾Æ´Ï¶ó, ¼ÒºñÀÚ Çൿ°ú ±×°ÍÀÌ Á¦Á¶ ºñ¿ë ¶Ç´Â ±¸¸Å µ¿Çâ¿¡ ¹ÌÄ¡´Â ¿µÇâÀ»º¸´Ù ¸íÈ®ÇÏ°Ô ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù.

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • À¯ÀüÀÚ Ä¡·á¿Í ¸ÂÃãÇü ÀÇ·á¿¡¼­ÀÇ ÄÄÇÇÅÏÆ® ¼¿ÀÇ ÀÀ¿ë È®´ë
    • ÄÄÇÇÅÏÆ® ¼¿¸¦ ÀÌ¿ëÇÑ °íµµÀÇ Á¶»ç¸¦ ÇÊ¿ä·Î ÇÏ´Â ¸¸¼º ÁúȯÀÇ À¯º´·üÀÇ »ó½Â
    • ÇüÁúÀüȯ È¿À²À» ³ôÀÎ »õ·Î¿î ¿ª·® ¼¿ ±ÕÁÖÀÇ °³¹ß
    • ¼¼Æ÷±â¼ú Çâ»óÀ» À§ÇÑ ¿¬±¸±â°ü°ú »ý¸í°øÇбâ¾÷ °£ÀÇ °øµ¿¿¬±¸ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ÀϺΠÄÄÇÇÅÏÆ® ¼¿ÁÖÀÇ ÇüÁúÀüȯ È¿À²¿¡ ÇѰ谡 ÀÖ°í, º¹ÀâÇÑ À¯ÀüÀÚ ½ÇÇè¿¡¼­ÀÇ »ç¿ë¿¡ Á¦¾àÀ» ºÎ°úÇÑ´Ù
    • »ý»ê ¹× º¸Á¸°ú °ü·ÃµÈ ºñ¿ëÀÌ ³ô°í ¼Ò±Ô¸ð ¹× Çмú ¿¬±¸¿¡ ´ëÇÑ ÀÀ¿ëÀ» ¹æÇØÇÕ´Ï´Ù.
  • ½ÃÀå ±âȸ
    • »ê¾÷ ±Ô¸ðÀÇ »ý¸í°øÇÐ °øÁ¤¿¡¼­ ¿ª·® ¼¿ÀÇ È¿À²°ú ¼öÀ² Çâ»ó
    • °í¼º´É ÄÄÇÇÅÏÆ® ¼¿¿¡ ÀÇÇÑ ³ó¾÷ ¹ÙÀÌ¿À Å×Å©³î·ÎÁö È®´ë ½ÃÀå °¡´É¼º
    • ȯ°æ ¹ÙÀÌ¿À Å×Å©³î·ÎÁö¿¡¼­ÀÇ ÄÄÇÇÅÏÆ® ¼¿ÀÇ °øÇØ ¹æÁö¿Í ¹ÙÀÌ¿À ·¹¹Ìµð¿¡À̼ǿ¡ÀÇ ¿ëµµ
  • ½ÃÀåÀÇ °úÁ¦
    • ÄÄÇÇÅÏÆ® ¼¿¸¦ »ç¿ëÇÏ¿© Á¦ÀÛµÈ À¯ÀüÀÚ ÀçÁ¶ÇÕ »ý¹°(GMO)ÀÇ ½ÂÀΰú »ó¾÷È­¿¡ À־ÀÇ ±ÔÁ¦»óÀÇ Àå¾Ö¹°
    • ÄÄÇÇÅÏÆ® ¼¿ ±â¼ú¿¡ ÀÇÇØ ÃËÁøµÇ´Â À¯ÀüÀÚ º¯Çü¿¡ °üÇÑ À±¸®Àû ¿ì·Á¿Í ÀÏ¹Ý ½Ã¹ÎÀÇ ÀÎ½Ä ¹®Á¦

Porter's Five Forces : ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀåÀ» Ž»öÇÏ´Â Àü·« µµ±¸

Porter's Five Forces Framework´Â ½ÃÀå »óȲ°æÀï ±¸µµ¸¦ ÀÌÇØÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. Porter's Five Forces Framework´Â ±â¾÷ÀÇ °æÀïÀ» Æò°¡Çϰí Àü·«Àû ±âȸ¸¦ ޱ¸ÇÏ´Â ¸íÈ®ÇÑ ±â¼úÀ» ¼³¸íÇÕ´Ï´Ù. ÀÌ ÇÁ·¹ÀÓ¿öÅ©´Â ±â¾÷ÀÌ ½ÃÀå ³» ¼¼·Âµµ¸¦ Æò°¡ÇÏ°í ½Å±Ô »ç¾÷ÀÇ ¼öÀͼºÀ» °áÁ¤ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÌ·¯ÇÑ ÀλçÀÌÆ®À» ÅëÇØ ±â¾÷Àº ÀÚ»çÀÇ °­Á¡À» Ȱ¿ëÇÏ°í ¾àÁ¡À» ÇØ°áÇϰí ÀáÀçÀûÀÎ °úÁ¦¸¦ ÇÇÇÒ ¼ö ÀÖÀ¸¸ç º¸´Ù °­ÀÎÇÑ ½ÃÀå¿¡¼­ÀÇ Æ÷Áö¼Å´×À» È®º¸ÇÒ ¼ö ÀÖ½À´Ï´Ù.

PESTLE ºÐ¼® : ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå¿¡¼­ ¿ÜºÎ ¿µÇâÀ» ÆÄ¾Ç

¿ÜºÎ °Å½Ã ȯ°æ ¿äÀÎÀº ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀåÀÇ ¼º°ú ¿ªÇÐÀ» Çü¼ºÇϴµ¥ ¸Å¿ì Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. Á¤Ä¡Àû, °æÁ¦Àû, »çȸÀû, ±â¼úÀû, ¹ýÀû, ȯ°æÀû ¿äÀÎ ºÐ¼®Àº ÀÌ·¯ÇÑ ¿µÇâÀ» Ž»öÇÏ´Â µ¥ ÇÊ¿äÇÑ Á¤º¸¸¦ ¼³¸íÇÕ´Ï´Ù. PESTLE ¿äÀÎÀ» Á¶»çÇÔÀ¸·Î½á ±â¾÷Àº ÀáÀçÀûÀÎ À§Çè°ú ±âȸ¸¦ ´õ Àß ÀÌÇØÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ±â¾÷Àº ±ÔÁ¦, ¼ÒºñÀÚ ¼±È£, °æÁ¦ µ¿ÇâÀÇ º¯È­¸¦ ¿¹ÃøÇÏ°í ¾ÕÀ¸·Î ¿¹»óµÇ´Â Àû±ØÀûÀÎ ÀÇ»ç °áÁ¤À» ÇÒ Áغñ¸¦ ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå Á¡À¯À² ºÐ¼® ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå °æÀï ±¸µµ ÆÄ¾Ç

ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀåÀÇ »ó¼¼ÇÑ ½ÃÀå Á¡À¯À² ºÐ¼®À» ÅëÇØ °ø±Þ¾÷üÀÇ ¼º°ú¸¦ Á¾ÇÕÀûÀ¸·Î Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ±â¾÷Àº ¼öÀÍ, °í°´ ±â¹Ý, ¼ºÀå·ü µî ÁÖ¿ä ÁöÇ¥¸¦ ºñ±³ÇÏ¿© °æÀï Æ÷Áö¼Å´×À» ¹àÈú ¼ö ÀÖ½À´Ï´Ù. ÀÌ ºÐ¼®À» ÅëÇØ ½ÃÀå ÁýÁß, ¼¼ºÐÈ­ ¹× ÅëÇÕ µ¿ÇâÀ» ¹àÇô³»°í °ø±Þ¾÷ü´Â °æÀïÀÌ Ä¡¿­ÇØÁö¸é¼­ ÀÚ½ÅÀÇ ÁöÀ§¸¦ ³ôÀÌ´Â Àü·«Àû ÀÇ»ç °áÁ¤À» ³»¸®´Â µ¥ ÇÊ¿äÇÑ Áö½ÄÀ» ¾òÀ» ¼ö ÀÖ½À´Ï´Ù.

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º ¿ª·® ¼¿ ½ÃÀå¿¡¼­ °ø±Þ¾÷üÀÇ ¼º´É Æò°¡

FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º´Â ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå¿¡¼­ °ø±Þ¾÷ü¸¦ Æò°¡ÇÏ´Â Áß¿äÇÑ µµ±¸ÀÔ´Ï´Ù. ÀÌ Çà·ÄÀ» ÅëÇØ ºñÁî´Ï½º Á¶Á÷Àº °ø±Þ¾÷üÀÇ ºñÁî´Ï½º Àü·«°ú Á¦Ç° ¸¸Á·µµ¸¦ ±âÁØÀ¸·Î Æò°¡ÇÏ¿© ¸ñÇ¥¿¡ ¸Â´Â ÃæºÐÇÑ Á¤º¸¸¦ ¹ÙÅÁÀ¸·Î ÀÇ»ç °áÁ¤À» ³»¸± ¼ö ÀÖ½À´Ï´Ù. ³× °¡Áö »çºÐ¸éÀ» ÅëÇØ °ø±Þ¾÷ü¸¦ ¸íÈ®Çϰí Á¤È®ÇÏ°Ô ¼¼ºÐÈ­ÇÏ¿© Àü·« ¸ñÇ¥¿¡ °¡Àå ÀûÇÕÇÑ ÆÄÆ®³Ê ¹× ¼Ö·ç¼ÇÀ» ÆÄ¾ÇÇÒ ¼ö ÀÖ½À´Ï´Ù.

Àü·« ºÐ¼® ¹× ±ÇÀå ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå¿¡¼­ ¼º°ø¿¡ ´ëÇÑ ±æÀ» ±×¸³´Ï´Ù.

ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀåÀÇ Àü·« ºÐ¼®Àº ½ÃÀå¿¡¼­ÀÇ Á¸À縦 °­È­ÇÏ·Á´Â ±â¾÷¿¡ ÇʼöÀûÀÔ´Ï´Ù. ÁÖ¿ä ÀÚ¿ø, ´É·Â ¹× ¼º°ú ÁöÇ¥¸¦ °ËÅäÇÔÀ¸·Î½á ±â¾÷Àº ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇÏ°í °³¼±À» À§ÇØ ³ë·ÂÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌ Á¢±Ù¹ýÀ» ÅëÇØ °æÀï ±¸µµ¿¡¼­ °úÁ¦¸¦ ±Øº¹ÇÏ°í »õ·Î¿î ºñÁî´Ï½º ±âȸ¸¦ Ȱ¿ëÇÏ¿© Àå±âÀûÀÎ ¼º°øÀ» °ÅµÑ ¼ö Àִ üÁ¦¸¦ ¸¶·ÃÇÒ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ º¸°í¼­´Â ÁÖ¿ä °ü½É ºÐ¾ß¸¦ ´Ù·ç´Â ½ÃÀå¿¡ ´ëÇÑ Á¾ÇÕÀûÀÎ ºÐ¼®À» Á¦°øÇÕ´Ï´Ù.

1. ½ÃÀå ħÅõ : ÇöÀç ½ÃÀå ȯ°æÀÇ »ó¼¼ÇÑ °ËÅä, ÁÖ¿ä ±â¾÷ÀÇ ±¤¹üÀ§ÇÑ µ¥ÀÌÅÍ, ½ÃÀå µµ´Þ¹üÀ§ ¹× Àü¹ÝÀûÀÎ ¿µÇâ·Â Æò°¡.

2. ½ÃÀå °³Ã´µµ : ½ÅÈï ½ÃÀåÀÇ ¼ºÀå ±âȸ¸¦ ÆÄ¾ÇÇϰí, ±âÁ¸ ºÎ¹®¿¡¼­ÀÇ È®Àå °¡´É¼ºÀ» Æò°¡Çϸç, ¹Ì·¡ ¼ºÀåÀ» À§ÇÑ Àü·«Àû ·Îµå¸ÊÀ» ¼³¸íÇÕ´Ï´Ù.

3. ½ÃÀå ´Ù¾çÈ­ : ÃÖ±Ù Á¦Ç° Ãâ½Ã, ¹Ì°³Ã´ Áö¿ª, ¾÷°èÀÇ ÁÖ¿ä Áøº¸, ½ÃÀåÀ» Çü¼ºÇÏ´Â Àü·«Àû ÅõÀÚ¸¦ ºÐ¼®ÇÕ´Ï´Ù.

4. °æÀï Æò°¡ ¹× Á¤º¸ : °æÀï ±¸µµ¸¦ öÀúÈ÷ ºÐ¼®ÇÏ¿© ½ÃÀå Á¡À¯À², »ç¾÷ Àü·«, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÀÎÁõ, ±ÔÁ¦ ´ç±¹ ½ÂÀÎ, ƯÇã µ¿Çâ, ÁÖ¿ä ±â¾÷ÀÇ ±â¼ú Áøº¸ µîÀ» °ËÁõÇÕ´Ï´Ù.

5. Á¦Ç° °³¹ß ¹× Çõ½Å : ¹Ì·¡ ½ÃÀå ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹»óµÇ´Â ÃÖ÷´Ü ±â¼ú, R&D Ȱµ¿, Á¦Ç° Çõ½ÅÀ» °­Á¶ÇÕ´Ï´Ù.

¶ÇÇÑ ÀÌÇØ°ü°èÀÚ°¡ ÃæºÐÇÑ Á¤º¸¸¦ ¾òÀº ÈÄ ÀÇ»ç°áÁ¤ÇÒ ¼ö ÀÖµµ·Ï Áß¿äÇÑ Áú¹®¿¡µµ ´ë´äÇϰí ÀÖ½À´Ï´Ù.

1. ÇöÀç ½ÃÀå ±Ô¸ð¿Í ÇâÈÄ ¼ºÀå ¿¹ÃøÀº?

2. ÃÖ°íÀÇ ÅõÀÚ ±âȸ¸¦ Á¦°øÇÏ´Â Á¦Ç°, Áö¿ªÀº ¾îµðÀԴϱî?

3. ½ÃÀåÀ» Çü¼ºÇÏ´Â ÁÖ¿ä ±â¼ú µ¿Çâ°ú ±ÔÁ¦ÀÇ ¿µÇâÀº?

4. ÁÖ¿ä º¥´õÀÇ ½ÃÀå Á¡À¯À²°ú °æÀï Æ÷Áö¼ÇÀº?

5. º¥´õ ½ÃÀå ÁøÀÔ, ö¼ö Àü·«ÀÇ ¿øµ¿·ÂÀÌ µÇ´Â ¼öÀÍ¿ø°ú Àü·«Àû ±âȸ´Â ¹«¾ùÀΰ¡?

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå Á¶»ç ¹æ¹ý

Á¦3Àå ÁÖ¿ä ¿ä¾à

Á¦4Àå ½ÃÀå °³¿ä

Á¦5Àå ½ÃÀå ÀλçÀÌÆ®

  • ½ÃÀå ¿ªÇÐ
    • ¼ºÀå ÃËÁø¿äÀÎ
      • À¯ÀüÀÚ Ä¡·á¿Í ¸ÂÃãÇü ÀÇ·á¿¡ À־ÀÇ À¯´ÉÇÑ ¼¿ÀÇ ÀÀ¿ë Áõ°¡
      • ¸¸¼º Áúȯ Áõ°¡¿¡ ¼ö¹ÝÇØ, ¿ª·® ¼¿À» »ç¿ëÇÑ °íµµÀÇ Á¶»ç°¡ ÇÊ¿ä
      • ÇüÁúÀüȯ È¿À²À» ³ôÀÎ »õ·Î¿î ÄÄÇÇÅÏÆ® ¼¿ÁÖ °³¹ß
      • ¼¼Æ÷±â¼ú Çâ»óÀ» ¸ñÀûÀ¸·Î ÇÑ ¿¬±¸±â°ü°ú »ý¸í°øÇбâ¾÷ °£ÀÇ Çù·Â È®´ë
    • ¾ïÁ¦¿äÀÎ
      • ÀϺΠÄÄÇÇÅÏÆ® ¼¿ÁÖÀÇ ÇüÁúÀüȯ È¿À²ÀÌ Á¦ÇѵǾî Àֱ⠶§¹®¿¡ º¹ÀâÇÑ À¯ÀüÀÚ ½ÇÇè¿¡¼­ÀÇ »ç¿ë¿¡ Á¦¾àÀÌ ÀÖ´Ù
      • ÄÄÇÇÅÏÆ® ¼¿ÀÇ »ý»ê°ú º¸°ü°ú °ü·ÃµÈ ³ôÀº ºñ¿ëÀÌ ¼Ò±Ô¸ð ¹× Çмú ¿¬±¸ÀÇ ÀÀ¿ëÀ» ¹æÇØÇϰí ÀÖ½À´Ï´Ù
    • ±âȸ
      • »ê¾÷ ±Ô¸ðÀÇ »ý¸í °øÇÐ °øÁ¤ÀÇ ¿ª·® ¼¿ È¿À² ¹× ¼öÀ² Çâ»ó
      • °í¼º´É ³ó¾÷ »ý¸í°øÇÐ È®´ë¿¡ À־ ½ÃÀåÀÇ °¡´É¼º ¿ª·®¼¿
      • ¿À¿° Á¦¾î ¹× ¹ÙÀÌ¿À ¼ö¸®¸¦ À§ÇÑ È¯°æ ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö¿¡ À־ÀÇ À¯´ÉÇÑ ¼¿ÀÇ ¿ëµµ
    • °úÁ¦
      • ÄÄÇÇÅÏÆ® ¼¿¸¦ »ç¿ëÇÏ¿© »ý¼ºµÈ À¯ÀüÀÚ º¯Çü »ý¹°Ã¼(GMO)ÀÇ ½ÂÀΰú »ó¾÷È­¿¡ À־ ±ÔÁ¦»óÀÇ Àå¾Ö¹°
      • ÄÄÇÇÅÏÆ® ¼¿ ±â¼ú¿¡ ÀÇÇÑ À¯ÀüÀÚ º¯Çü¿¡ °üÇÑ À±¸®Àû ¿ì·Á¿Í ±¹¹ÎÀÇ ÀνÄÀÇ ¹®Á¦
  • ½ÃÀå ¼¼ºÐÈ­ ºÐ¼®
  • Porter's Five Forces ºÐ¼®
  • PESTEL ºÐ¼®
    • Á¤Ä¡
    • °æÁ¦
    • »çȸ
    • ±â¼ú
    • ¹ý·ü
    • ȯ°æ

Á¦6Àå ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå : ¿ëµµº°

  • ¼Ò°³
  • »ý¸í°øÇÐ
    • À¯ÀüÀÚ °øÇÐ
    • ´Ü¹éÁú ¹ßÇö
  • ÀÓ»ó ¿¬±¸
    • Áø´Ü
    • Ä¡·á°³¹ß
  • »ê¾÷
    • ¹ÙÀÌ¿À Àüȯ
    • ¹ßÈ¿
  • Á¦¾à
    • â¾à
    • ¹é½Å °³¹ß
  • ¿¬±¸°³¹ß
    • ¹ÙÀÌ¿ÀÀÎÆ÷¸Åƽ½º
    • ¹Ì»ý¹°ÇÐ
    • ºÐÀÚ »ý¹°ÇÐ

Á¦7Àå ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå : ¼¼Æ÷ À¯Çüº°

  • ¼Ò°³
  • ´ëÀå±Õ ÄÄÇÇÅÏÆ® ¼¿
    • ÄɹÌÄà ÄÄÇÇÅÏÆ® ´ëÀå±Õ
    • ÀÏ·ºÆ®·Î ÄÄÇÇÅÏÆ® ´ëÀå±Õ
  • Æ÷À¯·ù ÄÄÇÇÅÏÆ® ¼¿
    • CHO ¼¼Æ÷
    • HEK ¼¼Æ÷
  • ±âŸ ¼¼±Õ ÄÄÇÇÅÏÆ® ¼¿
    • °íÃʱÕ
    • À¯»ê±Õ
  • È¿¸ð ÄÄÇÇÅÏÆ® ¼¿
    • P. pastoris
    • S. cerevisiae

Á¦8Àå ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼Ò°³
  • Çмú¿¬±¸±â°ü
    • ºñ¿µ¸®¿¬±¸¼¾ÅÍ
    • ´ëÇÐ
  • ³ó¾÷ ¿¬±¸ ±â°ü
  • ¹ÙÀÌ¿ÀÅ×Å©³î·¯Áö ±â¾÷
    • È®¸³µÈ »ý¸í°øÇÐ
    • ½ºÅ¸Æ®¾÷ »ý¸í°øÇÐ
  • °è¾à ¿¬±¸ ±â°ü
  • Á¦¾àȸ»ç

Á¦9Àå ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå : Á¦Ç° Á¦°ø Á¦Ç°º°

  • ¼Ò°³
  • ¿ª·® ¼¿ ŰƮ
    • È­ÇÐ º¯È¯ ŰƮ
    • ÀÏ·ºÆ®·ÎÆ÷·¹ÀÌ¼Ç Å°Æ®
  • ½Ã¾à ¹× ¼Ò¸ðǰ
    • Ç×»ýÁ¦
    • ¼ºÀå ¹Ìµð¾î
    • Çö󽺹̵å
  • ¼­ºñ½º
    • Ä¿½ºÅÒ Å¬·Î´× ¼­ºñ½º
    • Ä¿½ºÅÒ ´Ü¹éÁú ¹ßÇö ¼­ºñ½º

Á¦10Àå ÄÄÇÇÅÏÆ® ¼¿ ½ÃÀå : ±â¼úº°

  • ¼Ò°³
  • È­ÇÐ º¯È¯
  • ÀÏ·ºÆ®·ÎÆ÷·¹À̼Ç

Á¦11Àå ¾Æ¸Þ¸®Ä«ÀÇ À¯´ÉÇÑ ¼¿ ½ÃÀå

  • ¼Ò°³
  • ¾Æ¸£ÇîÆ¼³ª
  • ºê¶óÁú
  • ij³ª´Ù
  • ¸ß½ÃÄÚ
  • ¹Ì±¹

Á¦12Àå ¾Æ½Ã¾ÆÅÂÆò¾çÀÇ À¯´ÉÇÑ ¼¿ ½ÃÀå

  • ¼Ò°³
  • È£ÁÖ
  • Áß±¹
  • Àεµ
  • Àεµ³×½Ã¾Æ
  • ÀϺ»
  • ¸»·¹À̽þÆ
  • Çʸ®ÇÉ
  • ½Ì°¡Æ÷¸£
  • Çѱ¹
  • ´ë¸¸
  • ű¹
  • º£Æ®³²

Á¦13Àå À¯·´, Áßµ¿ ¹× ¾ÆÇÁ¸®Ä«ÀÇ À¯´ÉÇÑ ¼¿ ½ÃÀå

  • ¼Ò°³
  • µ§¸¶Å©
  • ÀÌÁýÆ®
  • Çɶõµå
  • ÇÁ¶û½º
  • µ¶ÀÏ
  • À̽º¶ó¿¤
  • ÀÌÅ»¸®¾Æ
  • ³×´ú¶õµå
  • ³ªÀÌÁö¸®¾Æ
  • ³ë¸£¿þÀÌ
  • Æú¶õµå
  • īŸ¸£
  • ·¯½Ã¾Æ
  • »ç¿ìµð¾Æ¶óºñ¾Æ
  • ³²¾ÆÇÁ¸®Ä«
  • ½ºÆäÀÎ
  • ½º¿þµ§
  • ½ºÀ§½º
  • ÅÍŰ
  • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
  • ¿µ±¹

Á¦14Àå °æÀï ±¸µµ

  • ½ÃÀå Á¡À¯À² ºÐ¼®(2023³â)
  • FPNV Æ÷Áö¼Å´× ¸ÅÆ®¸¯½º(2023³â)
  • °æÀï ½Ã³ª¸®¿À ºÐ¼®
  • Àü·« ºÐ¼®°ú Á¦¾È
BJH 24.11.07

The Competent Cells Market was valued at USD 2.01 billion in 2023, expected to reach USD 2.21 billion in 2024, and is projected to grow at a CAGR of 8.76%, to USD 3.62 billion by 2030.

Competent cells are essential in molecular biology for the uptake of foreign DNA during the transformation process, with a significant scope in biotechnology research, genetic engineering, and pharmaceutical development. These cells are chemically or electrically treated to increase membrane permeability to DNA. The necessity of competent cells spans their application in cloning techniques, protein expression, and genetic modification, serving as fundamental tools for laboratories focused on genetic engineering and synthetic biology. The end-use scope covers academic research institutions, pharmaceutical companies, and biotechnology firms, with these cells critical for crucial operations like gene cloning and pharmaceutical production.

KEY MARKET STATISTICS
Base Year [2023] USD 2.01 billion
Estimated Year [2024] USD 2.21 billion
Forecast Year [2030] USD 3.62 billion
CAGR (%) 8.76%

Market insights reveal the growth of the competent cells market driven by advances in synthetic biology, increased funding for recombinant technology, and rising demand for biopharmaceuticals. Continued innovation in genetic engineering amplifies the demand for competent cells, propelling market expansion. Opportunities arise from advancements in CRISPR technologies and next-generation therapeutic development, creating potential partnerships and investment avenues for stakeholders. Emphasizing regional market expansion, particularly in Asia-Pacific due to burgeoning biotech sectors and favorable government initiatives, is recommended to capture emerging growth opportunities.

Conversely, limitations include high costs associated with production and ethical concerns regarding genetic manipulation that could stymie market advancement. Regulatory hurdles and stringent approval processes present further challenges. Innovation and research can focus on enhancing the efficiency of DNA uptake, developing cost-effective and higher competency strains, and improving cryopreservation techniques for preserving cell viability. Streamlining production processes and investing in automated platforms can optimize manufacturing and scalability. The nature of the market is highly dynamic, characterized by rapid technological advancements and a competitive landscape filled with established and emerging players vying for market share. By aligning technological innovations with industry demands and addressing regulatory challenges, companies can achieve sustained growth and competitive advantage.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Competent Cells Market

The Competent Cells Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • increased application of competent cells in gene therapy and personalized medicine
    • rising prevalence of chronic diseases necessitating advanced research using competent cells
    • development of new competent cell strains with enhanced transformation efficiency
    • growing collaborations between research institutions and biotechnology companies to improve cell technologies
  • Market Restraints
    • Limited efficiency in transformation of some competent cell strains imposing constraints on usage in complex genetic experiments
    • High costs associated with production and storage of competent cells hindering small-scale and academic research applications
  • Market Opportunities
    • Enhancing the efficiency and yield of competent cells for industrial-scale biotechnology processes
    • Market potential in expanding agricultural biotechnology with high-performance competent cells
    • Applications of competent cells in environmental biotechnology for pollution control and bio-remediation
  • Market Challenges
    • Regulatory hurdles in approval and commercialization of genetically modified organisms (GMOs) created using competent cells
    • Ethical concerns and public perception issues regarding genetic modifications facilitated by competent cell technologies

Porter's Five Forces: A Strategic Tool for Navigating the Competent Cells Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Competent Cells Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Competent Cells Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Competent Cells Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Competent Cells Market

A detailed market share analysis in the Competent Cells Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Competent Cells Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Competent Cells Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Competent Cells Market

A strategic analysis of the Competent Cells Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Competent Cells Market, highlighting leading vendors and their innovative profiles. These include Addgene, Agilent Technologies, Bio-Rad Laboratories, BioDynamics Laboratory, Bioneer Corporation, Cayman Chemical Company, Cell Applications, Edge BioSystems, GenScript Biotech, Lucigen Corporation, Merck Group, New England Biolabs, OriGene Technologies, Promega Corporation, QIAGEN, Scarab Genomics, Takara Bio, Thermo Fisher Scientific, Yeastern Biotech, and Zymo Research.

Market Segmentation & Coverage

This research report categorizes the Competent Cells Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Application, market is studied across Biotechnology, Clinical Research, Industrial, Pharmaceutical, and Research and Development. The Biotechnology is further studied across Genetic Engineering and Protein Expression. The Clinical Research is further studied across Diagnostics and Therapeutic Development. The Industrial is further studied across Bioconversion and Fermentation. The Pharmaceutical is further studied across Drug Discovery and Vaccine Development. The Research and Development is further studied across Bioinformatics, Microbiology, and Molecular Biology.
  • Based on Cell Type, market is studied across E. coli Competent Cells, Mammalian Competent Cells, Other Bacterial Competent Cells, and Yeast Competent Cells. The E. coli Competent Cells is further studied across Chemically Competent E. coli and Electrocompetent E. coli. The Mammalian Competent Cells is further studied across CHO Cells and HEK Cells. The Other Bacterial Competent Cells is further studied across B. subtilis and L. lactis. The Yeast Competent Cells is further studied across P. pastoris and S. cerevisiae.
  • Based on End User, market is studied across Academic and Research Institutes, Agricultural Research Organizations, Biotech Companies, Contract Research Organizations, and Pharmaceutical Companies. The Academic and Research Institutes is further studied across Non-profit Research Centers and Universities. The Biotech Companies is further studied across Established Biotechs and Startup Biotechs.
  • Based on Product Offerings, market is studied across Competent Cell Kits, Reagents and Consumables, and Services. The Competent Cell Kits is further studied across Chemical Transformation Kits and Electroporation Kits. The Reagents and Consumables is further studied across Antibiotics, Growth Media, and Plasmids. The Services is further studied across Custom Cloning Services and Custom Protein Expression Services.
  • Based on Technology, market is studied across Chemical Transformation and Electroporation.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. increased application of competent cells in gene therapy and personalized medicine
      • 5.1.1.2. rising prevalence of chronic diseases necessitating advanced research using competent cells
      • 5.1.1.3. development of new competent cell strains with enhanced transformation efficiency
      • 5.1.1.4. growing collaborations between research institutions and biotechnology companies to improve cell technologies
    • 5.1.2. Restraints
      • 5.1.2.1. Limited efficiency in transformation of some competent cell strains imposing constraints on usage in complex genetic experiments
      • 5.1.2.2. High costs associated with production and storage of competent cells hindering small-scale and academic research applications
    • 5.1.3. Opportunities
      • 5.1.3.1. Enhancing the efficiency and yield of competent cells for industrial-scale biotechnology processes
      • 5.1.3.2. Market potential in expanding agricultural biotechnology with high-performance competent cells
      • 5.1.3.3. Applications of competent cells in environmental biotechnology for pollution control and bio-remediation
    • 5.1.4. Challenges
      • 5.1.4.1. Regulatory hurdles in approval and commercialization of genetically modified organisms (GMOs) created using competent cells
      • 5.1.4.2. Ethical concerns and public perception issues regarding genetic modifications facilitated by competent cell technologies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Competent Cells Market, by Application

  • 6.1. Introduction
  • 6.2. Biotechnology
    • 6.2.1. Genetic Engineering
    • 6.2.2. Protein Expression
  • 6.3. Clinical Research
    • 6.3.1. Diagnostics
    • 6.3.2. Therapeutic Development
  • 6.4. Industrial
    • 6.4.1. Bioconversion
    • 6.4.2. Fermentation
  • 6.5. Pharmaceutical
    • 6.5.1. Drug Discovery
    • 6.5.2. Vaccine Development
  • 6.6. Research and Development
    • 6.6.1. Bioinformatics
    • 6.6.2. Microbiology
    • 6.6.3. Molecular Biology

7. Competent Cells Market, by Cell Type

  • 7.1. Introduction
  • 7.2. E. coli Competent Cells
    • 7.2.1. Chemically Competent E. coli
    • 7.2.2. Electrocompetent E. coli
  • 7.3. Mammalian Competent Cells
    • 7.3.1. CHO Cells
    • 7.3.2. HEK Cells
  • 7.4. Other Bacterial Competent Cells
    • 7.4.1. B. subtilis
    • 7.4.2. L. lactis
  • 7.5. Yeast Competent Cells
    • 7.5.1. P. pastoris
    • 7.5.2. S. cerevisiae

8. Competent Cells Market, by End User

  • 8.1. Introduction
  • 8.2. Academic and Research Institutes
    • 8.2.1. Non-profit Research Centers
    • 8.2.2. Universities
  • 8.3. Agricultural Research Organizations
  • 8.4. Biotech Companies
    • 8.4.1. Established Biotechs
    • 8.4.2. Startup Biotechs
  • 8.5. Contract Research Organizations
  • 8.6. Pharmaceutical Companies

9. Competent Cells Market, by Product Offerings

  • 9.1. Introduction
  • 9.2. Competent Cell Kits
    • 9.2.1. Chemical Transformation Kits
    • 9.2.2. Electroporation Kits
  • 9.3. Reagents and Consumables
    • 9.3.1. Antibiotics
    • 9.3.2. Growth Media
    • 9.3.3. Plasmids
  • 9.4. Services
    • 9.4.1. Custom Cloning Services
    • 9.4.2. Custom Protein Expression Services

10. Competent Cells Market, by Technology

  • 10.1. Introduction
  • 10.2. Chemical Transformation
  • 10.3. Electroporation

11. Americas Competent Cells Market

  • 11.1. Introduction
  • 11.2. Argentina
  • 11.3. Brazil
  • 11.4. Canada
  • 11.5. Mexico
  • 11.6. United States

12. Asia-Pacific Competent Cells Market

  • 12.1. Introduction
  • 12.2. Australia
  • 12.3. China
  • 12.4. India
  • 12.5. Indonesia
  • 12.6. Japan
  • 12.7. Malaysia
  • 12.8. Philippines
  • 12.9. Singapore
  • 12.10. South Korea
  • 12.11. Taiwan
  • 12.12. Thailand
  • 12.13. Vietnam

13. Europe, Middle East & Africa Competent Cells Market

  • 13.1. Introduction
  • 13.2. Denmark
  • 13.3. Egypt
  • 13.4. Finland
  • 13.5. France
  • 13.6. Germany
  • 13.7. Israel
  • 13.8. Italy
  • 13.9. Netherlands
  • 13.10. Nigeria
  • 13.11. Norway
  • 13.12. Poland
  • 13.13. Qatar
  • 13.14. Russia
  • 13.15. Saudi Arabia
  • 13.16. South Africa
  • 13.17. Spain
  • 13.18. Sweden
  • 13.19. Switzerland
  • 13.20. Turkey
  • 13.21. United Arab Emirates
  • 13.22. United Kingdom

14. Competitive Landscape

  • 14.1. Market Share Analysis, 2023
  • 14.2. FPNV Positioning Matrix, 2023
  • 14.3. Competitive Scenario Analysis
  • 14.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Addgene
  • 2. Agilent Technologies
  • 3. Bio-Rad Laboratories
  • 4. BioDynamics Laboratory
  • 5. Bioneer Corporation
  • 6. Cayman Chemical Company
  • 7. Cell Applications
  • 8. Edge BioSystems
  • 9. GenScript Biotech
  • 10. Lucigen Corporation
  • 11. Merck Group
  • 12. New England Biolabs
  • 13. OriGene Technologies
  • 14. Promega Corporation
  • 15. QIAGEN
  • 16. Scarab Genomics
  • 17. Takara Bio
  • 18. Thermo Fisher Scientific
  • 19. Yeastern Biotech
  • 20. Zymo Research
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦